Solara Active Pharma Sciences (NSE:SOLARAPP1) Piotroski F-Score: 5 (As of Jul. 04, 2026) — Near Median


NSE:SOLARAPP1 Solara Active Pharma Sciences Ltd NSE:SOLARAPP1
67 GF Score
Price ₹267.45
GF Value ₹263.62
! 3 Warning Signs
View Full Analysis

What is Solara Active Pharma Sciences Piotroski F-Score?

Solara Active Pharma Sciences NSE:SOLARAPP1 67 Piotroski F-Score is 5 as of Jul. 04, 2026, which is at its 10-year median of 5.00. GuruFocus rates NSE:SOLARAPP1 with a GF Score™ of 67/100 and a GF Value™ of ₹263.62. The stock has 3 warning signs investors should review. Among 981 Drug Manufacturers companies, Solara Active Pharma Sciences ranks better than 61.57% on this metric.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Solara Active Pharma Sciences has an F-score of 5 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for Solara Active Pharma Sciences's Piotroski F-Score or its related term are showing as below:

NSE:SOLARAPP1' s Piotroski F-Score Range Over the Past 10 Years
Min: 4   Med: 5   Max: 7
Current: 5

During the past 10 years, the highest Piotroski F-Score of Solara Active Pharma Sciences was 7. The lowest was 4. And the median was 5.

Solara Active Pharma Sciences  (NSE:SOLARAPP1) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Solara Active Pharma Sciences Piotroski F-Score Related Terms


Solara Active Pharma Sciences Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for Solara Active Pharma Sciences's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Solara Active Pharma Sciences Piotroski F-Score Chart

Solara Active Pharma Sciences Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 4.00 4.00 7.00 5.00

Solara Active Pharma Sciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.00 0.00 0.00 0.00 5.00

NSE:SOLARAPP1 vs ZTS, UTHR: Piotroski F-Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Solara Active Pharma Sciences's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Solara Active Pharma Sciences Piotroski F-Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Solara Active Pharma Sciences's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Solara Active Pharma Sciences's Piotroski F-Score falls into.


NSE:SOLARAPP1
67GF Score
Solara Active Pharma Sciences Ltd NSE:SOLARAPP1
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Net Income was ₹-74 Mil.
Cash Flow from Operations was ₹1,529 Mil.
Revenue was ₹13,690 Mil.
Gross Profit was ₹6,845 Mil.
Average Total Assets from the begining of this year (Mar25)
to the end of this year (Mar26) was (22318.4 + 23325.9) / 2 = ₹22822.15 Mil.
Total Assets at the begining of this year (Mar25) was ₹22,318 Mil.
Long-Term Debt & Capital Lease Obligation was ₹1,297 Mil.
Total Current Assets was ₹8,581 Mil.
Total Current Liabilities was ₹8,939 Mil.
Net Income was ₹5 Mil.

Revenue was ₹12,838 Mil.
Gross Profit was ₹6,574 Mil.
Average Total Assets from the begining of last year (Mar24)
to the end of last year (Mar25) was (23509.6 + 22318.4) / 2 = ₹22914 Mil.
Total Assets at the begining of last year (Mar24) was ₹23,510 Mil.
Long-Term Debt & Capital Lease Obligation was ₹1,316 Mil.
Total Current Assets was ₹7,287 Mil.
Total Current Liabilities was ₹9,441 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Solara Active Pharma Sciences's current Net Income (TTM) was -74. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Solara Active Pharma Sciences's current Cash Flow from Operations (TTM) was 1,529. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Mar25)
=-74.1/22318.4
=-0.00332013

ROA (Last Year)=Net Income/Total Assets (Mar24)
=5.4/23509.6
=0.00022969

Solara Active Pharma Sciences's return on assets of this year was -0.00332013. Solara Active Pharma Sciences's return on assets of last year was 0.00022969. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Solara Active Pharma Sciences's current Net Income (TTM) was -74. Solara Active Pharma Sciences's current Cash Flow from Operations (TTM) was 1,529. ==> 1,529 > -74 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Mar26)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar25 to Mar26
=1296.6/22822.15
=0.05681323

Gearing (Last Year: Mar25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar24 to Mar25
=1316.3/22914
=0.05744523

Solara Active Pharma Sciences's gearing of this year was 0.05681323. Solara Active Pharma Sciences's gearing of last year was 0.05744523. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Mar26)=Total Current Assets/Total Current Liabilities
=8581/8939.1
=0.95994004

Current Ratio (Last Year: Mar25)=Total Current Assets/Total Current Liabilities
=7287.3/9441.1
=0.7718698

Solara Active Pharma Sciences's current ratio of this year was 0.95994004. Solara Active Pharma Sciences's current ratio of last year was 0.7718698. ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Solara Active Pharma Sciences's number of shares in issue this year was 44.107. Solara Active Pharma Sciences's number of shares in issue last year was 38.571. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=6844.7/13689.8
=0.49998539

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=6573.5/12837.6
=0.51205054

Solara Active Pharma Sciences's gross margin of this year was 0.49998539. Solara Active Pharma Sciences's gross margin of last year was 0.51205054. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Mar25)
=13689.8/22318.4
=0.61338626

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Mar24)
=12837.6/23509.6
=0.54605778

Solara Active Pharma Sciences's asset turnover of this year was 0.61338626. Solara Active Pharma Sciences's asset turnover of last year was 0.54605778. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+1+0+1+1+1+0+0+1
=5

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Solara Active Pharma Sciences has an F-score of 5 indicating the company's financial situation is typical for a stable company.

Frequently Asked Questions Learn more about Piotroski F-Score →
What does a Piotroski F-Score of 5 mean?
Solara Active Pharma Sciences (NSE:SOLARAPP1) has a Piotroski F-Score of 5 as of Jul. 04, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Solara Active Pharma Sciences and its competitors. This is near median its historical median of 5.00. Over the past decade, Solara Active Pharma Sciences' Piotroski F-Score has ranged from 4.00 to 7.00. According to the industry distribution chart, Solara Active Pharma Sciences ranks #377 out of 981 companies in the Drug Manufacturers industry, placing it in the top 38.4%.
Is Solara Active Pharma Sciences' Piotroski F-Score too high?
Solara Active Pharma Sciences' current Piotroski F-Score of 5 is near median its 10-year median of 5.00. Over the past 10 years, this metric has ranged from a low of 4.00 to a high of 7.00. The Drug Manufacturers industry median Piotroski F-Score is 5.00. Solara Active Pharma Sciences' value of 5 is 0% at this industry median. Based on the distribution chart, Solara Active Pharma Sciences ranks #377 out of 981 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Solara Active Pharma Sciences has a GF Score™ of 67/100, reflecting its overall financial health beyond just this single metric.
How does Solara Active Pharma Sciences' Piotroski F-Score compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Solara Active Pharma Sciences ranks #377 out of 981 companies for Piotroski F-Score. This puts Solara Active Pharma Sciences in the upper half of its industry. The industry median Piotroski F-Score is 5.00. Solara Active Pharma Sciences' value of 5 is 0% at this benchmark. Historically, Solara Active Pharma Sciences' own Piotroski F-Score has ranged from 4.00 to 7.00 over the past decade. While the company's 10-year median is 5.00 vs. the industry median of 5.00, Solara Active Pharma Sciences has consistently been at the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Drug Manufacturers company?
The median Piotroski F-Score among Drug Manufacturers companies is 5.00, based on 981 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Solara Active Pharma Sciences's current Piotroski F-Score of 5 is 0% at the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Solara Active Pharma Sciences and its competitors. For the Drug Manufacturers industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Solara Active Pharma Sciences's current Piotroski F-Score is 5, which is near median its own 10-year median of 5.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Solara Active Pharma Sciences stock overvalued right now?
Solara Active Pharma Sciences (NSE:SOLARAPP1) has a current Piotroski F-Score of 5. The stock's GF Value™ is ₹263.62, compared to a current price of ₹267.45 — trading 1.5% above its estimated fair value. The current Piotroski F-Score is 5, which is near median its 10-year median of 5.00 and 0% at the Drug Manufacturers industry median of 5.00. Solara Active Pharma Sciences' overall GF Score™ is 67/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Solara Active Pharma Sciences (NSE:SOLARAPP1), the current Piotroski F-Score is 5 as of Jul. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Solara Active Pharma Sciences (NSE:SOLARAPP1) Overvalued in 2026?

Based on GuruFocus' analysis, Solara Active Pharma Sciences stock appears to be overvalued. The current stock price of ₹267.45 is trading 1.5% above its estimated GF Value™ of ₹263.62.

Key valuation signals for NSE:SOLARAPP1:

  • Piotroski F-Score: 5 (near median its 10-year median of 5.00)
  • GF Value™: ₹263.62 vs. price of ₹267.45 (1.5% above fair value)
  • GF Score™: 67/100 with 3 warning signs
  • Industry Position: 0% at the Drug Manufacturers median (#377 of 981)

No single metric tells the full story. See the NSE:SOLARAPP1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Solara Active Pharma Sciences Business Description

Other Exchanges SOLARA:India541540:India
Address Phase II - CSIR Road, Module No. 601, 602, 603, Ticel Bio Park, Taramani, Chennai, TN, IND, 600113
Solara Active Pharma Sciences Ltd is engaged in the Active Pharmaceutical Ingredients (API) in India. It manufactures and develops APIs and offers services, including CRAMS and contract manufacturing for APIs. The company offers products and services, such as Anaesthetic, Analgesics, Antiviral, Retinoid, Anti-emetic, Antimalarial, Diuretic, Muscle relaxant, Antiallergics, Antihypertensive, Calcimimetic agent, Anti-seizure, Antigout, Cardiovascular, Anti-infective, Cough suppressant, and others. It also offers contract services, including contract development and manufacturing, and analytical services. Geographically, the company generates all of its revenue from India.
67GF Score

Get the complete analysis for NSE:SOLARAPP1

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹267.45
Price
₹263.62
GF Value